SAGE Therapeutics Now Covered by Analysts at JPMorgan Chase & Co. (SAGE)
Analysts at JPMorgan Chase & Co. assumed coverage on shares of SAGE Therapeutics (NASDAQ:SAGE) in a research report issued to clients and investors on Tuesday, TheFlyOnTheWall.com reports. The firm set an “overweight” rating on the stock.
Shares of SAGE Therapeutics (NASDAQ:SAGE) opened at 33.40 on Tuesday. SAGE Therapeutics has a 52 week low of $24.25 and a 52 week high of $34.88. The stock’s 50-day moving average is $28.74 and its 200-day moving average is $28.74. The company’s market cap is $833.7 million.
A number of other firms have also recently commented on SAGE. Analysts at Goldman Sachs initiated coverage on shares of SAGE Therapeutics in a research note on Tuesday. They set a “neutral” rating on the stock. Analysts at Leerink Swann initiated coverage on shares of SAGE Therapeutics in a research note on Tuesday. They set an “outperform” rating on the stock.
SAGE Therapeutics, Inc is a biopharmaceutical company. The Company is focused on development and commercialization of therapies for the treatment of life-threatening, rare central nervous system (NASDAQ:SAGE) disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.